Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.

BMC Cancer · 2018 · PMC6300002 · PMID 30567533

Europe PMC DOI

hedged sentence

0.0960

closest p · 1.9× alpha

0.0960

boldest claim

The sentences

did not reach statistical significancep = 0.096so close (0.05 < p ≤ 0.1)

The sensitivity analysis suggested a marginal benefit for cabozantinib versus axitinib for PFS ( p = 0.050); however, the differences in OS did not reach statistical significance ( p = 0.096).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.